In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...
2don MSN
For a disease afflicting 35.5 million people in the U.S., chronic kidney disease flies under the radar. Only half the people ...
The US Food and Drug Administration (FDA) has broadened the approval of Furoscix (furosemide injection) to treat edema in ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
6d
March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...
Announced the acceptance of the New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis. The FDA set a ...
Millions of people take medications known as proton pump inhibitors (PPIs) to relieve heartburn, acid reflux, and related ...
Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
News-Medical.Net on MSN1d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback